---
title: "Polaryx Therapeutics, Inc. (PLYX.US) — 公司概况"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/PLYX.US/overview.md"
symbol: "PLYX.US"
name: "Polaryx Therapeutics, Inc."
parent: "https://longbridge.com/zh-CN/quote/PLYX.US.md"
datetime: "2026-04-15T21:44:22.780Z"
locales:
  - [en](https://longbridge.com/en/quote/PLYX.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PLYX.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PLYX.US/overview.md)
---

# Polaryx Therapeutics, Inc. (PLYX.US) — 公司概况

## 基本信息

| 项目 | 详情 |
|------|--------|
| 行业 | 制药 |
| 交易所 | US Market |
| 地址 | South Tower, 140 E Ridgewood Avenue, Suite 415, Paramus, New Jersey, United States |
| 官网 | [olaryx.com](https://olaryx.com) |

## 公司简介

Polaryx Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于在美国发现、开发和商业化用于治疗罕见和儿童溶酶体储存疾病的疾病修饰疗法。其产品管线包括 PLX-100，一种临床前阶段的口服组合疗法；PLX-200，一种用于治疗溶酶体储存疾病的重新开发的口服小分子；PLX-300，一种临床前阶段的口服组合疗法；以及 PLX-400，一种临床前阶段的新型基因治疗候选药物。该公司成立于 2014 年，总部位于新泽西州帕拉默斯

## 核心管理层

| 名称 | 职位 |
|------|-------|
| Alex Yang | CEO & Chair of Board |
| G. Michael Landis | CFO & Director |
| Andrew John O | Chief Investment Officer |
| Lisa L. Bollinger | Chief Medical Officer |
| Shrijay Vijayan | Chief Scientific & Business Development Officer |
| Francis A. Braun | Independent Director |
| Mitchel S. Berger | Independent Director |
| Charles S. Ryan | Independent Director |

## 主要股东

| 名称 | 占比 | 报告日期 |
|------|-------|-------------|
| Mstone Partners Hong Kong Limited | 47.43% | 2026-01-29 |
| Gershon Koh | 11.67% | 2026-01-12 |
| Rush University Medical Center | 8.04% | 2026-01-12 |
| Jae-Hoon Kim | 5.35% | 2026-01-12 |
| Hahn-Jun Lee | 4.96% | 2026-01-12 |
| Laputa Cooperative | 4.36% | 2026-01-12 |
| Healutyx, Co., Ltd | 3.49% | 2026-01-12 |
| Jung Jun Lee | 2.35% | 2026-01-12 |
| Sangcheon Mun | 2.11% | 2026-01-12 |
| Meridian Holdings Co., Ltd. | 1.06% | 2026-01-12 |


---

> **免责声明: 本文仅供参考，不构成任何投资建议。**